Immatics presents IMA402 and IMA203CD8 clinical data at ESMO 2026

Immatics presented clinical results at ESMO 2026 for its PRAME-targeting pipeline. IMA402 showed a 32% confirmed objective response rate, 12.5-month median duration of response and 91% 1-year overall survival in advanced melanoma patients with high PRAME expression. The company also completed Phase 1a dose escalation for IMA203CD8 and is enrolling uterine cancer patients.

Detected & updated continuously · Source: Nebula